Checked against the sources listed at the end of this page on November 4, 2026.
The rule behind the answer
Medicare drug plans (Part D) follow a federal list of drug uses they may leave out. The Part D definition excludes drugs "which may be excluded from coverage or otherwise restricted under Medicaid under sections 1927(d)(2) or (d)(3) of the Act, except for smoking cessation agents" (42 CFR 423.100), and that Medicaid list includes "Agents when used for anorexia, weight loss, or weight gain." (42 U.S.C. 1396r-8(d)(2)(A)).
So the question is never only which medicine. It is which medicine, for which use.
Uses Medicare drug plans cover
CMS says: "Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) indications are eligible for Part D coverage." (CMS, Medicare GLP-1 Bridge information for providers).
- Ozempic and Mounjaro are FDA-approved to improve blood sugar control in type 2 diabetes (Mounjaro for adults and children 10 years and older), a use Medicare drug plans cover under each plan's drug list and rules.
- Zepbound is FDA-approved for sleep apnea: the FDA "approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity" (FDA, December 20, 2024).
- Wegovy prescribed to reduce the risk of major cardiovascular events, in adults with established cardiovascular disease and either obesity or overweight, stays with the Part D plan, according to CMS's June 10, 2026 guidance to drug plans (CMS memo).
Each plan still applies its own drug list and rules, such as prior authorization. The Medicare prior authorization guide has the deadlines.
For weight loss: the Medicare GLP-1 Bridge
Medicare.gov: "Starting July 1, 2026, Medicare covers these GLP-1 drugs:" Foundayo (tablet), Wegovy (injection or tablet) and Zepbound, KwikPen only ("The program doesn't cover single-dose ZepboundĀ® vials or pens"). CMS sets the window "between July 1, 2026, and December 31, 2027" and says "The Medicare GLP-1 Bridge will operate outside of the Medicare Part D benefit's coverage and payment flow." (CMS, Medicare GLP-1 Bridge).
The cost
"You'll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug)." (Medicare.gov).
Who qualifies, in Medicare.gov's words
"You must be 18 or older," and one of these applies:
- "You have a body mass index (BMI) of 35 or higher."
- "You have a BMI of 30 or higher and you have at least one of these conditions:" diastolic heart failure (heart failure with preserved ejection fraction), uncontrolled high blood pressure, or chronic kidney disease at stage 3a or higher.
- "You have a BMI of 27 or higher and have at least one of these conditions:" prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms.
Medicare.gov says the Bridge is not for people who "Already get GLP-1 drugs covered through your Medicare Part D plan" or who "Have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease"; for those uses, the Part D plan is the route.
Which Medicare coverage it works with
Medicare.gov lists "A standalone Medicare drug plan (PDP)", "A Medicare Advantage (MA) coordinated care plan with drug coverage" "(including HMO, HMOPOS, and Local and Regional PPO plans)", "A Special Needs Plan (SNP)", "An Employer/union group waiver plan (EGWP)" and "The Limited Income Newly Eligible Transition (LI NET) program".
Prior authorization under the Bridge
"Your prior authorization is valid (including for refills and dose changes) through December 31, 2027" (Medicare.gov), unless you change GLP-1 medicines.
What comes next
CMS's BALANCE model page describes the Bridge as collecting data "ahead of potential implementation of BALANCE in Part D" (CMS, BALANCE model). Until CMS sets that step, the Bridge's dates above are the ones in effect.
Common questions
Does Medicare cover Wegovy for weight loss?
Since July 1, 2026, the Medicare GLP-1 Bridge covers Wegovy (injection or tablet) for weight loss for people who meet its BMI and health-condition rules, with a $50 copayment for a one-month supply, through December 31, 2027. It runs outside the Part D plan.
Does Medicare cover Zepbound?
For sleep apnea, Zepbound is a use Medicare drug plans cover under each plan's rules. For weight loss, the Medicare GLP-1 Bridge covers the Zepbound KwikPen for eligible people; it does not cover single-dose vials or pens.
Does Medicare cover Ozempic or Mounjaro?
Medicare drug plans cover them for type 2 diabetes under each plan's drug list and rules. The Medicare GLP-1 Bridge list is Foundayo, Wegovy and the Zepbound KwikPen.
How much does the Medicare GLP-1 Bridge cost?
Medicare.gov says you pay a $50 copayment to the pharmacy for a one-month supply, either 28 or 30 days depending on the drug.
Does the Bridge work with Medicare Advantage?
Medicare.gov lists Medicare Advantage coordinated care plans with drug coverage, including HMO, HMOPOS and Local and Regional PPO plans, along with standalone drug plans, Special Needs Plans, employer and union group waiver plans and the LI NET program.
Sources
- Medicare.gov, Weight loss drugs (Medicare GLP-1 Bridge): medicare.gov/coverage/weight-loss-drugs
- CMS, Medicare GLP-1 Bridge: cms.gov; information for providers: cms.gov
- CMS, Medicare GLP-1 Bridge: Expectations and Frequently Asked Questions for Part D Sponsors (June 10, 2026): cms.gov
- CMS, BALANCE model: cms.gov
- 42 CFR 423.100, definition of a Part D drug: eCFR; 42 U.S.C. 1396r-8(d)(2): govinfo.gov
- FDA, Zepbound for obstructive sleep apnea (December 20, 2024): fda.gov; FDA labels for Ozempic and Mounjaro: DailyMed, Ozempic, DailyMed, Mounjaro
Not medical advice and not a decision on your claim. Your doctor and your plan decide.